# ForCast Orthopedics, Inc.

> ForCast Orthopedics is a Denver-based, development-stage combination-device company modernizing the treatment of periprosthetic joint infection (PJI), a serious complication of joint replacement. Its proprietary Wearable Intra-Articular Infusion System (WIIS) delivers targeted, high-concentration antibiotic therapy directly into the infected joint to break through bacterial biofilm that defeats systemic antibiotics. Lead programs FC001 (vancomycin) and FC002 (tobramycin) both carry FDA QIDP designation, with FC001 also holding Orphan Drug designation. The company closed an initial Series A in August 2025 led by OrthoInnovations and is preparing for a clinical trial in 2026.

- **Headquarters:** Denver, Colorado, United States
- **Founders:** Peter Noymer (Co-Founder, Executive Chairman & CEO), Jared Foran (Co-Founder & Chief Scientific/Medical Officer)
- **Team size:** ~4 employees
- **Products:** WIIS (Wearable Intra-Articular Infusion System), FC001, FC002
- **Notable:** FDA QIDP designation for both FC001 and FC002, FDA Orphan Drug designation for lead program FC001, Eligibility for FDA Fast-Track designation and Priority Review

## Products & services

- **WIIS (Wearable Intra-Articular Infusion System)** — Proprietary delivery platform that automates targeted antibiotic infusion directly into an infected joint, creating a local antibiotic reservoir to disrupt biofilm. Integrates KORU Medical's FreedomEDGE infusion pump.
- **FC001** — Lead drug-device program using vancomycin for gram-positive periprosthetic joint infection. Holds FDA Orphan Drug and QIDP designations, with eligibility for Fast-Track and Priority Review.
- **FC002** — Second program using tobramycin for gram-negative periprosthetic joint infection. Holds FDA QIDP designation.

## Achievements

- FDA QIDP designation for both FC001 and FC002
- FDA Orphan Drug designation for lead program FC001
- Eligibility for FDA Fast-Track designation and Priority Review
- Initial close of Series A financing (August 2025) led by OrthoInnovations
- Partnership with KORU Medical Systems for infusion technology (September 2025)
- Selected for MedTech Innovator 2026 accelerator cohort
- Selected to present at Wilson Sonsini conference

## Latest updates

- **2026-06** — Selected for the MedTech Innovator 2026 accelerator cohort (≈65 of 1,800+ applicants).
- **2025-09** — Announced partnership with KORU Medical Systems to integrate the FreedomEDGE infusion pump into the WIIS platform; clinical trial targeted for 2026.
- **2025-08** — Announced initial close of Series A financing led by OrthoInnovations; Dr. Charles DeCook joins board as Chief Innovation Officer.

## Links

- Website: https://forcastortho.com
- LinkedIn: https://www.linkedin.com/company/forcast-ortho

---

Profile page: https://yespress.io/forcast-orthopedics-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-15